Entacapone

Entacapone

SCHEMBL3934631

CCN(CC)C(=O)/C(C#N)=C\c1cc(O)c(O)c([N+](=O)[O-])c1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

COMT

The experimentally established mechanism targets of Entacapone. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
COMT known ✓ P21964 5/20 1.00
FTO Q9C0B1 8/20 1.00
MEN1 O00255 2/20 1.00
KMT2A Q03164 2/20 1.00
ABCC3 O15438 1/20 1.00
ABCC4 O15439 1/20 1.00
ABCB11 O95342 1/20 1.00
LMNA P02545 1/20 1.00
CYP2C9 P11712 1/20 1.00
GPR35 Q9HC97 1/20 1.00
EGFR P00533 1/20 0.62
ALDH1A1 P00352 1/20 0.60
MAPT P10636 1/20 0.60
HPGD P15428 1/20 0.60
RECQL P46063 1/20 0.60

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Entacapone SCHEMBL3395296 1.00 FTO (1.00) FTOCOMTMEN1KMT2AABCC3
Entacapone SCHEMBL34505 1.00 FTO (1.00) FTOCOMTMEN1KMT2AABCC3
Entacapone SCHEMBL29356206 1.00 FTO (1.00) FTOCOMTMEN1KMT2AABCC3
Entacapone SCHEMBL34504 1.00 FTO (1.00) FTOCOMTMEN1KMT2AABCC3
Entacapone SCHEMBL29406523 1.00 FTO (1.00) FTOCOMTMEN1KMT2AABCC3
Entacapone SCHEMBL27766815 0.99 FTO (0.98) FTOCOMTMEN1KMT2AABCC3
Entacapone SCHEMBL4940150 0.98 FTO (0.96) FTOCOMTMEN1KMT2AABCC3
Entacapone SCHEMBL4940155 0.98 FTO (0.96) FTOCOMTMEN1KMT2AABCC3
Entacapone SCHEMBL26128138 0.97 FTO (0.94) FTOCOMTMEN1KMT2AABCC3
Entacapone SCHEMBL3972337 0.96 FTO (0.92) FTOCOMTMEN1KMT2AABCC3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2046730-A1 PROCESS AND PRODUCT PLIVA HRVATSKA d.o.o. (HR) 2009-04-15 EP claimed
WO-2008007093-A1 PROCESS AND PRODUCT PLIVA HRVATSKA D.O.O. (HR) 2008-01-17 WO claimed
EP-1701937-A4 STABLE POLYMORPHS OF (E)-N,N-DIETHYL-2-CYANO-3-(3,4-DIHYDROXY-5-NITROPHENYL)ACRYLAMIDE WOCKHARDT LTD (IN) 2007-05-02 EP claimed
EP-1701936-A4 AN EFFICIENT PROCESS FOR THE MANUFACTURE OF (E)-ENTACAPONE POLYMORPHIC FORM A WOCKHARDT LTD (IN) 2007-01-24 EP claimed
US-20070004935-A1 Efficient method for the manufacture of (E) -Entacapone polymorphic Form A WOCKHARDT LIMITED 2007-01-04 US claimed
EP-1701937-A1 STABLE POLYMORPHS OF (E)-N,N-DIETHYL-2-CYANO-3-(3,4-DIHYDROXY-5-NITROPHENYL)ACRYLAMIDE Wockhardt Limited (IN) 2006-09-20 EP claimed
EP-1701936-A1 AN EFFICIENT PROCESS FOR THE MANUFACTURE OF (E)-ENTACAPONE POLYMORPHIC FORM A Wockhardt Limited (IN) 2006-09-20 EP claimed
WO-2005070881-A1 AN EFFICIENT PROCESS FOR THE MANUFACTURE OF (E)-ENTACAPONE POLYMORPHIC FORM A WOCKHARDT LIMITED (IN) 2005-08-04 WO claimed
WO-2005066117-A1 STABLE POLYMORPHS OF (E)-N,N-DIETHYL-2-CYANO-3-(3,4-DIHYDROXY-5-NITROPHENYL)ACRYLAMIDE WOCKHARDT LIMITED (IN) 2005-07-21 WO claimed
WO-2014164667-A1 DENGUE AND WEST NILE VIRUS PROTEASE INHIBITORS GEORGETOWN UNIVERSITY (US) 2014-10-09 WO disclosed
US-20090326062-A1 PROCESS FOR PREPARING ENTACAPONE SUBSTANTIALLY FREE OF Z-ISOMER, SYNTHESIS INTERMEDIATES THEREOF AND A NEW CRYSTALLINE FORM Chemo Iberica, SA (ES) 2009-12-31 US disclosed
EP-1945607-B1 A PROCESS FOR THE PREPARATION OF HIGHLY PURE (E) N,N-DIETHYL-2-CYANO-3-(3,4-DIHYDROXY- 5-NITRO PHENYL) ACRYLAMIDE (ENTACAPONE) USV LTD (IN) 2009-10-14 EP disclosed
EP-2046730-A1 PROCESS AND PRODUCT PLIVA HRVATSKA d.o.o. (HR) 2009-04-15 EP disclosed
US-20080319226-A1 Process For the Preparation of Highly Pure (E) N,N-Diethyl-2-Cyano-3-(3,4-Dihydroxy-5-Nitro Phenyl) Acrylamide (Entacapone) USV LIMITED (IN) 2008-12-25 US disclosed
WO-2007094007-A1 AN IMPROVED PROCESS FOR THE PREPARATION OF ENTACAPONE SUVEN LIFE SCIENCES LTD., (IN) 2007-08-23 WO disclosed
WO-2007077572-A1 A PROCESS FOR THE PREPARATION OF ENTACAPONE FORM-A ACTAVIS GROUP PTC EHF (IS) 2007-07-12 WO disclosed
WO-2007054950-A1 A PROCESS FOR THE PREPARATION OF HIGHLY PURE (E) N,N-DIETHYL-2-CYANO-3-(3,4-DIHYDROXY- 5-NITRO PHENYL) ACRYLAMIDE (ENTACAPONE) USV LIMITED (IN) 2007-05-18 WO disclosed
US-20070060767-A1 Methods for the preparation of Entacapone SUVEN LIFE SCIENCES (IN) 2007-03-15 US disclosed
US-20070060767-A1 Methods for the preparation of Entacapone SUVEN LIFE SCIENCES (IN) 2007-03-15 US disclosed
WO-2005063693-A1 IMPROVED PROCESS FOR THE PREPARATION OF ENTACAPONE SUVEN LIFE SCIENCES LTD (IN) 2005-07-14 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080319226-A1 Process For the Preparation of Highly Pure (E) N,N-Diethyl-2-Cyano-3-(3,4-Dihydroxy-5-Nitro Phenyl) Acrylamide (Entacapone) GNE, ADH1A, ADH5 COMT 235/4885FTO 1781/4885MEN1 4625/4885
US-20070060767-A1 Methods for the preparation of Entacapone OTC, NAAA, GNE COMT 119/4885FTO 353/4885MEN1 1942/4885
US-20070004935-A1 Efficient method for the manufacture of (E) -Entacapone polymorphic Form A COMT, GNE, GNMT COMT 1/4885FTO 93/4885MEN1 3678/4885
US-20090326062-A1 PROCESS FOR PREPARING ENTACAPONE SUBSTANTIALLY FREE OF Z-ISOMER, SYNTHESIS INTERMEDIATES THEREOF AND A NEW CRYSTALLINE FORM GNE, ENTPD5, ENTPD1 COMT 452/4885FTO 1687/4885MEN1 2601/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.